Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | CD4 | P01730 | 3/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840308 | 1.00 | ACHE (0.46) | ACHECD4GPR183MEN1KMT2A | |
| SCHEMBL16755539 | 1.00 | ACHE (0.46) | ACHECD4GPR183MEN1KMT2A | |
| SCHEMBL19840313 | 0.93 | CD4 (0.47) | ACHECD4MEN1KMT2ACYP1A2 | |
| SCHEMBL15562368 | 0.93 | CD4 (0.47) | ACHECD4MEN1KMT2ACYP1A2 | |
| SCHEMBL15562369 | 0.93 | CD4 (0.47) | ACHECD4MEN1KMT2ACYP1A2 | |
| SCHEMBL16755587 | 0.90 | ACHE (0.48) | ACHECD4MEN1KMT2ACYP1A2 | |
| SCHEMBL19840306 | 0.90 | ACHE (0.48) | ACHECD4MEN1KMT2ACYP1A2 | |
| SCHEMBL15561380 | 0.90 | ACHE (0.48) | ACHECD4MEN1KMT2ACYP1A2 | |
| SCHEMBL16755583 | 0.89 | KMT2A (0.49) | ACHEGPR183MEN1KMT2ACARM1 | |
| SCHEMBL16769875 | 0.89 | KMT2A (0.49) | ACHEGPR183MEN1KMT2ACARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884825-B2 | Curcumin analogs and methods of making and using thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150152056-A1 | Curcumin Analogs and Methods of Making and Using Thereof | UNIVERSITY OF DELHI (IN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152056-A1 | Curcumin Analogs and Methods of Making and Using Thereof | COX15, HCCS, HMOX2 | ACHE 3174/4885CD4 4747/4885GPR183 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.